[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 10
1. de Korwin JD: [Eradication of Helicobacter pylori. Is it necessary to eradicate Helicobacter pylori in gastric reflux?]. Presse Med; 2001 Sep 22;30(26):1313-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Eradication d'Helicobacter pylori. Faut-il éradiquer Helicobacter pylori en cas de pathologie de reflux?
  • PYLORI: Epidemiological studies have not demonstrated an association between H. pylori infection and symptoms of gastroesophageal reflux, reflux esophagitis, or Barrett's esophagus with or without dysplasia or esophageal adenocarcinoma.
  • In addition, eradication of H. pylori could favor he development of gastroesophageal reflux or reflux esophagitis.
  • Eradication of H. pylori reduces the efficacy of antisecretory drugs according to poorly understood mechanisms.
  • [MeSH-major] Anti-Bacterial Agents. Anti-Ulcer Agents / therapeutic use. Drug Therapy, Combination / therapeutic use. Esophagitis, Peptic / drug therapy. Helicobacter Infections / drug therapy. Helicobacter pylori

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11603095.001).
  • [ISSN] 0755-4982
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anti-Ulcer Agents
  • [Number-of-references] 59
  •  go-up   go-down


2. Vakil N: Increasing compliance with long-term therapy: avoiding complications and adverse events. Rev Gastroenterol Disord; 2005;5 Suppl 2:S12-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, continuous medical therapy for erosive esophagitis is associated with fewer relapses and better outcomes.
  • Similarly, long-term therapy administered continuously reduces complications such as stricture and may decrease the development of dysplasia in Barrett's esophagus.
  • [MeSH-major] Barrett Esophagus / drug therapy. Gastroesophageal Reflux / drug therapy. Patient Compliance. Proton Pump Inhibitors
  • [MeSH-minor] Drug Administration Schedule. Gastrointestinal Agents / administration & dosage. Humans

  • MedlinePlus Health Information. consumer health - GERD.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16369223.001).
  • [ISSN] 1533-001X
  • [Journal-full-title] Reviews in gastroenterological disorders
  • [ISO-abbreviation] Rev Gastroenterol Disord
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gastrointestinal Agents; 0 / Proton Pump Inhibitors
  • [Number-of-references] 27
  •  go-up   go-down


3. Woodall CE, Li Y, Liu QH, Wo J, Martin RC: Chemoprevention of metaplasia initiation and carcinogenic progression to esophageal adenocarcinoma by resveratrol supplementation. Anticancer Drugs; 2009 Jul;20(6):437-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The effects of resveratrol on the initiation of Barrett's metaplasia and the carcinogenic progression to esophageal adenocarcinoma have not been evaluated.
  • The aim of this study was to evaluate the effects of resveratrol on the transition from reflux esophagitis to Barrett's metaplasia to dysplasia to esophageal adenocarcinoma in an established rat model.
  • Thirty-one animals in the 5-month resveratrol group showed a decreased severity of esophagitis (P<0.0001), incidence of intestinal metaplasia (P = 0.3567), and incidence of carcinoma (P = 0.4590) as compared with both the saline and nonoperated control groups.
  • In conclusion, morphological characteristics consistent with decreased esophagitis and incidences of metaplasia and esophageal adenocarcinoma were seen on histopathology in the resveratrol group.
  • [MeSH-major] Anticarcinogenic Agents / therapeutic use. Esophageal Neoplasms / prevention & control. Esophagus / drug effects. Stilbenes / therapeutic use
  • [MeSH-minor] Animals. Apoptosis / drug effects. Catalase / metabolism. Disease Models, Animal. Disease Progression. Glutathione / metabolism. Immunohistochemistry. In Situ Nick-End Labeling. Male. Metaplasia. Oxidative Stress / drug effects. Rats. Rats, Sprague-Dawley. Superoxide Dismutase / metabolism. Thiobarbituric Acid Reactive Substances / metabolism

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. RESVERATROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19398904.001).
  • [ISSN] 1473-5741
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Stilbenes; 0 / Thiobarbituric Acid Reactive Substances; EC 1.11.1.6 / Catalase; EC 1.15.1.1 / Superoxide Dismutase; GAN16C9B8O / Glutathione; Q369O8926L / resveratrol
  •  go-up   go-down


Advertisement
4. Leodolter A, Penagini R: On-demand therapy is a valid strategy in GERD patients: pros and cons. Dig Dis; 2007;25(3):175-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On-demand treatment is less cost-saving in patients with esophagitis, and symptomatic/endoscopic relapses occur frequently in severe grades.
  • It is suggested that PPI continuous maintenance is more appropriate than on-demand therapy in patients with severe esophagitis, in those with Barrett's esophagus where chronic PPIs may reduce incidence of dysplasia, in uninvestigated elderly patients where esophagitis is more prevalent and it is more frequently complicated with gastrointestinal bleeding and possibly in uninvestigated or NERD patients with frequent clinical relapses.
  • [MeSH-major] Enzyme Inhibitors / administration & dosage. Gastroesophageal Reflux / drug therapy. Proton Pump Inhibitors
  • [MeSH-minor] Aged. Barrett Esophagus / drug therapy. Esophagitis, Peptic / drug therapy. Humans

  • MedlinePlus Health Information. consumer health - GERD.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 S. Karger AG, Basel
  • (PMID = 17827935.001).
  • [ISSN] 1421-9875
  • [Journal-full-title] Digestive diseases (Basel, Switzerland)
  • [ISO-abbreviation] Dig Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Proton Pump Inhibitors
  •  go-up   go-down


5. Bak YT: Management strategies for gastroesophageal reflux disease. J Gastroenterol Hepatol; 2004 Sep;19 Suppl 3:S49-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • When treating erosive esophagitis, PPI is better than H(2) receptor blockers in healing mucosal breaks and relieving symptoms.
  • Long-term maintenance PPI therapy is reported to be very effective in maintaining the remission of reflux esophagitis for up to 5 years.
  • On-demand PPI is also another good option for a maintenance therapy in erosive esophagitis.
  • In Barrett's esophagus, symptoms seem to be well-controlled with PPIs.
  • Unfortunately, however, PPIs have no effect on the shortening of Barrett's esophagus or in preventing the progression to dysplasia and adenocarcinoma.
  • [MeSH-major] Anti-Ulcer Agents / administration & dosage. Gastroesophageal Reflux / drug therapy. Histamine H2 Antagonists / administration & dosage. Proton Pump Inhibitors
  • [MeSH-minor] Barrett Esophagus / complications. Barrett Esophagus / drug therapy. Endoscopy, Gastrointestinal. Esophagitis / complications. Esophagitis / drug therapy. Humans. Practice Guidelines as Topic

  • Genetic Alliance. consumer health - Gastroesophageal Reflux.
  • MedlinePlus Health Information. consumer health - GERD.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15324382.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Anti-Ulcer Agents; 0 / Histamine H2 Antagonists; 0 / Proton Pump Inhibitors
  • [Number-of-references] 27
  •  go-up   go-down


6. Camilleri M: Gastroenterology and hepatology clinical research update: 2005-2006. Clin Gastroenterol Hepatol; 2006 Dec;4(12):1428-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The topics included eosinophilic esophagitis in children, detecting high-grade dysplasia or carcinoma in Barrett's esophagus, advances in management of celiac disease with elemental diet or gluten predigestion, the safety of NSAIDs in inflammatory bowel disease, the role of steroids in development of abscesses, prognosis of colorectal cancer associated with inflammatory bowel disease, screening for familial colorectal cancer in apparently sporadic disease, a new syndrome of familial colorectal cancer, new drugs in the treatment of chronic constipation and obesity, hepatoma risk factors and underserved racial/ethnic groups, and the application of new imaging and biology in diagnosis of gastroenterological disorders.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16949347.001).
  • [ISSN] 1542-3565
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 31
  •  go-up   go-down


7. Jankowski JA, Anderson M: Review article: management of oesophageal adenocarcinoma -- control of acid, bile and inflammation in intervention strategies for Barrett's oesophagus. Aliment Pharmacol Ther; 2004 Oct;20 Suppl 5:71-80; discussion 95-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Review article: management of oesophageal adenocarcinoma -- control of acid, bile and inflammation in intervention strategies for Barrett's oesophagus.
  • Oesophagitis is associated with Barrett's metaplasia in about 10% of individuals.
  • The UK has one of the highest world-wide prevalences of Barrett's metaplasia, with 1% of adults having the condition, resulting in an incidence of oesophageal adenocarcinoma two to three times that seen in either Europe or North America.
  • In addition, the conversion rate to cancer in individuals with Barrett's metaplasia in UK surveillance programmes is twice that observed in the USA (0.96% per year vs. 0.4% per year), lending further support to the notion that the UK is a high-risk region.
  • The evidence base on what can be achieved with medical therapy to reduce the risk of dysplasia or the development of adenocarcinoma needs to be strengthened with data from randomized controlled trials, as existing data have many limitations.
  • Patients with Barrett's metaplasia respond variably to proton pump inhibitor therapy (even high-dose therapy 'normalizes' acid reflux in only 85% of cases), and symptom control is a poor determinant of the adequacy of suppression of acid reflux.
  • Gastro-oesophageal reflux is implicated in the pathogenesis of Barrett's metaplasia, and ex vivo and in vitro evidence suggests that its attenuation reverses proliferation and biological variables over days, and perhaps the metaplastic histology to a degree over years.
  • Bile acids, present especially frequently in the refluxate of Barrett's oesophagus patients, are also likely to influence the development and persistence of metaplasia.
  • Barrett's metaplasia is replaced by a squamous epithelium when acid reflux is well controlled and the epithelium is physically destroyed by ablation with argon plasma coagulation or photodynamic therapy.
  • These modalities are invasive and are not likely to be useful in the routine management of patients with Barrett's oesophagus without dysplasia or cancer.
  • The use of non-steroidal anti-inflammatory drugs, including aspirin, is associated with a decreased incidence of oesophageal adenocarcinoma.
  • There is therefore a great need for randomized controlled trials to assess the outcomes of such chemopreventive therapy in patients with Barrett's metaplasia.
  • [MeSH-major] Barrett Esophagus / prevention & control. Bile / secretion. Esophageal Neoplasms / prevention & control. Esophagitis / prevention & control
  • [MeSH-minor] Chemoprevention / methods. Drug Costs. Gastroesophageal Reflux / prevention & control. Gastrointestinal Agents / therapeutic use. Humans. Risk Factors

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15456468.001).
  • [ISSN] 0269-2813
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Gastrointestinal Agents
  • [Number-of-references] 82
  •  go-up   go-down


8. O'Riordan JM, Byrne PJ, Ravi N, Keeling PW, Reynolds JV: Long-term clinical and pathologic response of Barrett's esophagus after antireflux surgery. Am J Surg; 2004 Jul;188(1):27-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term clinical and pathologic response of Barrett's esophagus after antireflux surgery.
  • BACKGROUND: The impact of antireflux surgery on outcome in Barrett's esophagus, in particular its effect on both the regression of metaplasia and the progression of metaplasia through dysplasia to adenocarcinoma, remains unclear.
  • This long-term follow-up study evaluated clinical, endoscopic, histopathologic, and physiologic parameters in patients with Barrett's esophagus who underwent antireflux surgery in a specialist unit.
  • METHODS: Between 1985 and 2001, 58 patients with Barrett's esophagus (49 long-segment and 9 short-segment) underwent a Rossetti-Nissen fundoplication, 32 via open procedure and 26 laparoscopically.
  • RESULTS: At a median follow-up of 59 months, 52 patients (90%) had excellent symptom control, whereas 6 patients (10%) had significant recurrent symptoms and were on regular proton pump inhibitor medication.
  • Thirty-five percent (20 of 57) of patients showed either partial or complete regression of Barrett's epithelium.
  • Six of 8 patients with preoperative low-grade dysplasia showed evidence of regression.
  • Dysplasia developed after surgery in 2 patients, and 2 patients developed adenocarcinoma at 4 and 7 years after surgery.
  • CONCLUSIONS: Nissen fundoplication provides excellent long-lasting relief of symptoms in patients with Barrett's esophagus and may promote regression of metaplasia and dysplasia.
  • Progression of Barrett's to dysplasia and tumor was only evident in patients with abnormal postoperative acid scores, suggesting that pH monitoring has an important role in the follow-up of surgically treated patients.
  • [MeSH-major] Barrett Esophagus / surgery. Esophagitis, Peptic / surgery. Fundoplication

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15219481.001).
  • [ISSN] 0002-9610
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Shaheen NJ: Advances in Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology; 2005 May;128(6):1554-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in Barrett's esophagus and esophageal adenocarcinoma.
  • This review focuses on the epidemiology of esophageal adenocarcinoma and its presumed precursor lesion, Barrett's esophagus; the pathogenesis of the cancer; advances in treatment of adenocarcinoma and Barrett's esophagus; and strategies for cancer prevention.
  • Recent evidence suggests that Barrett's esophagus is more prevalent in asymptomatic individuals than previously appreciated.
  • The pathogenesis of Barrett's esophagus is poorly understood.
  • Given that some subjects will have repeated bouts of severe erosive esophagitis and never develop Barrett's esophagus, host factors must play an important role.
  • Ablative therapies, as well as endoscopic mucosal resection, hold promise for those with superficial cancer or high-grade dysplasia.
  • The value of chemoprevention in subjects with dysplastic Barrett's esophagus by use of cyclooxygenase 2 inhibitors, nonsteroidal anti-inflammatory drugs, or proton pump inhibitors is unknown.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Barrett Esophagus / pathology. Barrett Esophagus / therapy. Esophageal Neoplasms / pathology. Esophageal Neoplasms / therapy

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15887151.001).
  • [ISSN] 0016-5085
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / K23DK59311-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Number-of-references] 130
  •  go-up   go-down


10. Abraham SC, Singh VK, Yardley JH, Wu TT: Hyperplastic polyps of the esophagus and esophagogastric junction: histologic and clinicopathologic findings. Am J Surg Pathol; 2001 Sep;25(9):1180-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hyperplastic polyps of the esophagus and esophagogastric junction region (EGJ) are uncommon lesions characterized by hyperplastic epithelium (foveolar-type, squamous, or both) with variable amounts of inflamed stroma.
  • Comprehensive histologic and clinicopathologic evaluation of these polyps, their association with background mucosal pathology, and their association with Barrett's esophagus has not been previously performed.
  • Most (80%) were composed of predominantly cardiac-type mucosa, predominantly squamous mucosa (17%), or an admixture (3%).
  • Intestinal metaplasia of the polyp was present in only 7% and low-grade dysplasia in only 3%.
  • In the majority of cases (67%) hyperplastic polyps were associated with concurrent or recent ulcers or erosive esophagitis.
  • In most cases (48%) esophageal injury was associated with GERD, but other potential etiologies included medications, infection, anastomotic or polypectomy sites, vomiting, and photodynamic therapy.
  • Four patients (15%) had Barrett's esophagus, three of whom had or developed dysplastic Barrett's mucosa.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Barrett Esophagus / complications. Barrett Esophagus / pathology. Epithelium. Esophagitis, Peptic / complications. Esophagitis, Peptic / pathology. Female. Gastroesophageal Reflux / complications. Gastroesophageal Reflux / pathology. Gastroscopy. Humans. Hyperplasia / etiology. Hyperplasia / pathology. Male. Middle Aged. Mucous Membrane

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11688578.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down






Advertisement